Table 2.

Primary endpoint: overall survival using Bayesian analysis

	Galunisertib + Lomustine N = 79	Galunisertib N = 39	Placebo + Lomustine N = 40	Primary Comparison: Galunisertib + Lomustine vs Placebo + Lomustine
Deaths	71	30	34
Censoring rate (%)	10.1	23.1	15.0
OS (months), median (95% CrI)a	6.7 (5.3, 8.5)	8.0 (5.7, 11.7)	7.5 (5.6, 10.3)
Hazard ratio (95% CrI)				1.13 (0.78, 1.65)
Posterior probability P (HR < 1)				0.26

^a 95% CrI = 95% Credible Interval. The denominator for response rates is the number of randomized patients per arm. All randomized patients had measureable disease at baseline.